Evidence Table D-52. Continuous neurological outcomes for studies comparing interventions to treat delirium

| Author, year | Study design | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Mean score, intervention | Mean score, control group | Relative risk (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |  |
| Agar, 2017[17](#_ENREF_17) | RCT | Patients in hospice and palliative care with delirium | Haloperidol (Max dose: 4 mg/d),  | Placebo (Max dose: 4 mg/day),  | Oral | Mean of Extra pyramidal symptom rating scale. | Not reported | Not reported | Mean difference 0.79 (95% CI: 0.17 to 1.41), p=0.01 |
| Second-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |  |
| Agar, 2017[17](#_ENREF_17) | RCT | Patients in hospice and palliative care with delirium | Risperidone (Max dose: 4 mg/d),  | Placebo (Max dose: 4 mg/day),  | Oral | Mean of Extra pyramidal symptom rating scale. | Not reported | Not reported | Mean difference 0.73 (95% CI: 0.09 to 1.37), p=0.03 |
| First-generation antipsychotic vs. first-generation antipsychotic |  |  |  |  |  |  |  |  |  |
| Breitbart, 1996[22](#_ENREF_22) | RCT | Medically hospitalized adult patients with AIDS and a DRS score of 13 or greater (delirium) | Haloperidol (Planned dose: oral: 0.25-5.0mg, Intramuscular: 0.125-3.0mg Mean dose: 1.4 Dose range: 0.4 - 3.6mg), 11 | Chlorpromazine (Planned dose: Oral: 10-200mg, Intramuscular: 5-100mg Mean dose: 36 Dose range: 10-80mg), 13 | Oral or intramuscular | Extrapyramidal Symptom Rating Scale: Parkinson’s subscale | Baseline: Mean 7 (SD 6.8)Final: Mean 5.54 (SD 6.76) | Baseline: Mean 7.42 (SD 8.08)Final: Mean 5.08 (SD 4.48) | 0.88 (95% CI: -29.37 to 31.13) |

| Author, year | Study design | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Mean score, intervention | Mean score, control group | Relative risk (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. second-generation antipsychotic |  |  |  |  |  |  |  |  |  |
| Maneeton, 2013[49](#_ENREF_49) | RCT | General adult population (age 18-75) with hyperactive delirium, referred to psychiatry consult liaison service at tertiary care hospital in Thailand | Quetiapine (Mean dose: 67.6 (SD 9.7) Dose range: 25-100mg), 24 | Haloperidol (Mean dose: 0.8 (SD 0.3) Dose range: 0.5-2.0mg), 28 | Oral | MSAS score | Baseline: Mean 0.1 (SD 0.5)Final: Mean 0.3 (SD 0.7) | Baseline: Mean 0.2 (SD 0.8)Final: Mean 0.3 (SD 1.1) | 0.10 (95% CI: -3.65 to 3.85) |
| Maneeton, 2013[49](#_ENREF_49) | RCT | General adult population (age 18-75) with hyperactive delirium, referred to psychiatry consult liaison service at tertiary care hospital in Thailand | Quetiapine (Mean dose: 67.6 (SD 9.7) Dose range: 25-100mg), 24 | Haloperidol (Mean dose: 0.8 (SD 0.3) Dose range: 0.5-2.0mg), 28 | Oral | MSAS score | Baseline: Mean 0.1 (SD 0.5)Final: Mean 0.3 (SD 0.7) | Baseline: Mean 0.2 (SD 0.8)Final: Mean 0.3 (SD 1.1) | 0.10 (95% CI: -3.65 to 3.85) |
| First-generation antipsychotic vs. other |  |  |  |  |  |  |  |  |  |
| Breitbart, 1996[22](#_ENREF_22) | RCT | Medically hospitalized adult patients with AIDS and a DRS score of 13 or greater (delirium) | Lorazepam (Planned dose: Oral: 0.50-4.0mg, Intramuscular: 0.2-2.0mg Mean dose: 4.6 Dose range: 1.3 - 7.9mg), 6 | Chlorpromazine (Planned dose: Oral: 10-200mg, Intramuscular: 5-100mg Mean dose: 36 Dose range: 10-80mg), 13 | Oral or intramuscular | Extrapyramidal Symptom Rating Scale: Parkinson’s subscale | Baseline: Mean 7.6 (SD 10.11)Final: Mean 12.2 (SD 8.93) | Baseline: Mean 7.42 (SD 8.08)Final: Mean 5.08 (SD 4.48) | 6.94 (95% CI: -23.88 to 37.76) |
| Breitbart, 1996[22](#_ENREF_22) | RCT | Medically hospitalized adult patients with AIDS and a DRS score of 13 or greater (delirium) | Lorazepam (Planned dose: Oral: 0.50-4.0mg, Intramuscular: 0.2-2.0mg Mean dose: 4.6 Dose range: 1.3 - 7.9mg), 6 | Haloperidol (Planned dose: oral: 0.25-5.0mg, Intramuscular: 0.125-3.0mg Mean dose: 1.4 Dose range: 0.4 - 3.6mg), 11 | Oral or intramuscular | Extrapyramidal Symptom Rating Scale: Parkinson’s subscale | Baseline: Mean 7.6 (SD 10.11)Final: Mean 12.2 (SD 8.93) | Baseline: Mean 7 (SD 6.8)Final: Mean 5.54 (SD 6.76) | 6.06 (95% CI: -27.11 to 39.23) |

AIDS=acquired immunodeficiency syndrome; CI=confidence interval; DRS=Delirium Rating Scale; Mg/day=milligram per day; Mg=milligram; P=p-value; SD=standard deviation